No-reflow reversibility

A study based on serial assessment of multiple biomarkers

Giampaolo Niccoli, Francesco Fracassi, Nicola Cosentino, Elena Falcioni, Marco Roberto, Giuseppe De Luca, Antonio Maria Leone, Francesco Burzotta, Italo Porto, Carlo Trani, Anna Severino, Filippo Crea

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

No-reflow after primary percutaneous coronary intervention (pPCI) may be reversible. 40 patients undergoing pPCI were evaluated by assessing either improvement or lack of changes regarding angiographic and electrocardiographic indexes of no-reflow between admission and pre-discharge. Myeloperoxidase (MPO; in nanograms per milliliter), C-reactive protein (CRP; in milligrams per liter), endothelin-1 (ET-1; in nanograms per milliliter), angiopoietin-2 (Ang-2, in picograms per milliliter), and their pre-discharge/basal values variations (Δ) were related to no-reflow evolution. ΔMPO and ΔCRP were greater in patients with sustained no-reflow or lack of ST-segment resolution (STR) as compared with those with reversible no-reflow or lack of STR (p = 0.033, p = 0.04, p <0.001, and p = 0.001, respectively), whereas ΔET-1 was similar in the two groups. ΔAng-2 was greater in patients with sustained no-reflow or lack of STR as compared with those with reversible no-reflow or lack of STR (p = 0.01 and 0.044, respectively). Bigger ΔMPO, ΔCRP (increasing levels), and ΔAng-2 (decreasing levels) are associated with sustained no-reflow, thus they might have a role in no-reflow evolution.

Original languageEnglish
Pages (from-to)798-807
Number of pages10
JournalJournal of Cardiovascular Translational Research
Volume6
Issue number5
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Biomarkers
Percutaneous Coronary Intervention
Angiopoietin-2
Endothelin-1
C-Reactive Protein
Peroxidase

Keywords

  • Inflammation
  • Neoangiogenesis
  • No-reflow
  • Primary percutaneous coronary intervention
  • ST-elevation myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

No-reflow reversibility : A study based on serial assessment of multiple biomarkers. / Niccoli, Giampaolo; Fracassi, Francesco; Cosentino, Nicola; Falcioni, Elena; Roberto, Marco; De Luca, Giuseppe; Leone, Antonio Maria; Burzotta, Francesco; Porto, Italo; Trani, Carlo; Severino, Anna; Crea, Filippo.

In: Journal of Cardiovascular Translational Research, Vol. 6, No. 5, 10.2013, p. 798-807.

Research output: Contribution to journalArticle

Niccoli, G, Fracassi, F, Cosentino, N, Falcioni, E, Roberto, M, De Luca, G, Leone, AM, Burzotta, F, Porto, I, Trani, C, Severino, A & Crea, F 2013, 'No-reflow reversibility: A study based on serial assessment of multiple biomarkers', Journal of Cardiovascular Translational Research, vol. 6, no. 5, pp. 798-807. https://doi.org/10.1007/s12265-013-9509-5
Niccoli, Giampaolo ; Fracassi, Francesco ; Cosentino, Nicola ; Falcioni, Elena ; Roberto, Marco ; De Luca, Giuseppe ; Leone, Antonio Maria ; Burzotta, Francesco ; Porto, Italo ; Trani, Carlo ; Severino, Anna ; Crea, Filippo. / No-reflow reversibility : A study based on serial assessment of multiple biomarkers. In: Journal of Cardiovascular Translational Research. 2013 ; Vol. 6, No. 5. pp. 798-807.
@article{8cb1d6bce8954d1790a0417a17267bb4,
title = "No-reflow reversibility: A study based on serial assessment of multiple biomarkers",
abstract = "No-reflow after primary percutaneous coronary intervention (pPCI) may be reversible. 40 patients undergoing pPCI were evaluated by assessing either improvement or lack of changes regarding angiographic and electrocardiographic indexes of no-reflow between admission and pre-discharge. Myeloperoxidase (MPO; in nanograms per milliliter), C-reactive protein (CRP; in milligrams per liter), endothelin-1 (ET-1; in nanograms per milliliter), angiopoietin-2 (Ang-2, in picograms per milliliter), and their pre-discharge/basal values variations (Δ) were related to no-reflow evolution. ΔMPO and ΔCRP were greater in patients with sustained no-reflow or lack of ST-segment resolution (STR) as compared with those with reversible no-reflow or lack of STR (p = 0.033, p = 0.04, p <0.001, and p = 0.001, respectively), whereas ΔET-1 was similar in the two groups. ΔAng-2 was greater in patients with sustained no-reflow or lack of STR as compared with those with reversible no-reflow or lack of STR (p = 0.01 and 0.044, respectively). Bigger ΔMPO, ΔCRP (increasing levels), and ΔAng-2 (decreasing levels) are associated with sustained no-reflow, thus they might have a role in no-reflow evolution.",
keywords = "Inflammation, Neoangiogenesis, No-reflow, Primary percutaneous coronary intervention, ST-elevation myocardial infarction",
author = "Giampaolo Niccoli and Francesco Fracassi and Nicola Cosentino and Elena Falcioni and Marco Roberto and {De Luca}, Giuseppe and Leone, {Antonio Maria} and Francesco Burzotta and Italo Porto and Carlo Trani and Anna Severino and Filippo Crea",
year = "2013",
month = "10",
doi = "10.1007/s12265-013-9509-5",
language = "English",
volume = "6",
pages = "798--807",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - No-reflow reversibility

T2 - A study based on serial assessment of multiple biomarkers

AU - Niccoli, Giampaolo

AU - Fracassi, Francesco

AU - Cosentino, Nicola

AU - Falcioni, Elena

AU - Roberto, Marco

AU - De Luca, Giuseppe

AU - Leone, Antonio Maria

AU - Burzotta, Francesco

AU - Porto, Italo

AU - Trani, Carlo

AU - Severino, Anna

AU - Crea, Filippo

PY - 2013/10

Y1 - 2013/10

N2 - No-reflow after primary percutaneous coronary intervention (pPCI) may be reversible. 40 patients undergoing pPCI were evaluated by assessing either improvement or lack of changes regarding angiographic and electrocardiographic indexes of no-reflow between admission and pre-discharge. Myeloperoxidase (MPO; in nanograms per milliliter), C-reactive protein (CRP; in milligrams per liter), endothelin-1 (ET-1; in nanograms per milliliter), angiopoietin-2 (Ang-2, in picograms per milliliter), and their pre-discharge/basal values variations (Δ) were related to no-reflow evolution. ΔMPO and ΔCRP were greater in patients with sustained no-reflow or lack of ST-segment resolution (STR) as compared with those with reversible no-reflow or lack of STR (p = 0.033, p = 0.04, p <0.001, and p = 0.001, respectively), whereas ΔET-1 was similar in the two groups. ΔAng-2 was greater in patients with sustained no-reflow or lack of STR as compared with those with reversible no-reflow or lack of STR (p = 0.01 and 0.044, respectively). Bigger ΔMPO, ΔCRP (increasing levels), and ΔAng-2 (decreasing levels) are associated with sustained no-reflow, thus they might have a role in no-reflow evolution.

AB - No-reflow after primary percutaneous coronary intervention (pPCI) may be reversible. 40 patients undergoing pPCI were evaluated by assessing either improvement or lack of changes regarding angiographic and electrocardiographic indexes of no-reflow between admission and pre-discharge. Myeloperoxidase (MPO; in nanograms per milliliter), C-reactive protein (CRP; in milligrams per liter), endothelin-1 (ET-1; in nanograms per milliliter), angiopoietin-2 (Ang-2, in picograms per milliliter), and their pre-discharge/basal values variations (Δ) were related to no-reflow evolution. ΔMPO and ΔCRP were greater in patients with sustained no-reflow or lack of ST-segment resolution (STR) as compared with those with reversible no-reflow or lack of STR (p = 0.033, p = 0.04, p <0.001, and p = 0.001, respectively), whereas ΔET-1 was similar in the two groups. ΔAng-2 was greater in patients with sustained no-reflow or lack of STR as compared with those with reversible no-reflow or lack of STR (p = 0.01 and 0.044, respectively). Bigger ΔMPO, ΔCRP (increasing levels), and ΔAng-2 (decreasing levels) are associated with sustained no-reflow, thus they might have a role in no-reflow evolution.

KW - Inflammation

KW - Neoangiogenesis

KW - No-reflow

KW - Primary percutaneous coronary intervention

KW - ST-elevation myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84885656898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885656898&partnerID=8YFLogxK

U2 - 10.1007/s12265-013-9509-5

DO - 10.1007/s12265-013-9509-5

M3 - Article

VL - 6

SP - 798

EP - 807

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 5

ER -